NeoPhore Limited

NeoPhore Limited is a small molecule neoantigen immuno-oncology company focused on developing a pipeline of small molecule drugs targeting novel proteins across the MMR pathway. Their first-in-class MMR inhibitors aim to improve clinical outcomes for cancer patients by inducing neoantigen expression and increasing immunogenicity in solid tumors. This approach makes the tumors more sensitive to immunotherapy.

Buy Funded Startups lists

Funding Round: Series B+

Funding Amount:

Date: 22-May-2024

Investors: Bristol Myers Squibb

Markets: Immuno-oncology, Oncology, Biotechnology, Drug Discovery, Small Molecule Therapeutics, Cancer, Genetics, and Translational Medicine

HQ: Cambridge, Cambridgeshire, United Kingdom

Founded: 2017

Website: https://www.neophore.com/

LinkedIn: https://www.linkedin.com/company/neophore-ltd

Twitter: https://twitter.com/neophoreltd

Instagram: